Results 181 to 190 of about 47,232 (218)

Beyond Hematology-Current Insights into Chimeric Antigen Receptor (CAR) T-Cell Therapy for Skin and Connective Tissue Disorders. [PDF]

Cells
Ciosek A, Hofmann J, Galant K, Marinkovich MP, Wierzbowska A, Ciążyńska M, Bień N, Narbutt J, Lesiak A.   +8 more
europepmc   +1 more source

Cutaneous Crystal‐Storing Histiocytosis With Marginal Zone Lymphoma. A Case Report With A Striking Clinical Presentation

Journal of Cutaneous Pathology, Volume 53, Issue 7, Page 576-580, July 2026.
ABSTRACT Cutaneous crystal‐storing histiocytosis (CSH) is an extremely rare histopathologic finding of histiocytes accumulating crystals of immunoglobulin or paraproteins, often associated with lymphoplasmacytic malignancies. It commonly presents in a wide age range of both female and male adults with a history of a lymphoproliferative disorder ...
Ashton Arlen, Brad S. Graham, Gregory A. Hosler, Marsha C. Kinney   +3 more
wiley   +1 more source

Exfoliative Erythroderma Revealing Primary Central Nervous System Diffuse Large B-Cell Lymphoma. [PDF]

Cureus
Bouchelkia I, Rosen T.
europepmc   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, Volume 117, Issue 1, Page 144-153, July 2026.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

Real-world lymphoma cohort in an HIV-endemic setting: cohort design, epidemiological features and impact of implementing novel classification standards. [PDF]

BMC Cancer
Andera LF, Chetty DR, Mohamed Z, Oelofse D, Bailey J, Brown K, Panchoo G, Antel K, Simba K, Kritzinger G, Cassim S, Ramburan A, Opie JJ, Louw VJ, Verburgh E.   +14 more
europepmc   +1 more source

Thymus and Leishmania at the Crossroads: Autoimmunity and Cancer

Immunology, Volume 178, Issue 3, Page 377-386, July 2026.
Conceptual ‘Crossroads Model’ linking Leishmania, thymic infection and immune dysregulation: an integrative model is proposed in which Leishmania infection disrupts thymic architecture and stromal–thymocyte interactions. These alterations converge to promote defective tolerance, increased autoimmune risk and a microenvironment permissive to malignant ...
Alef Batista Bezerra Barros, Gabriel Augusto Leite, Arthur Gomes de Andrade, Maria Danielma dos Santos Reis, Luiz Henrique Agra Cavalcante‐Silva, Marvin Paulo Lins   +5 more
wiley   +1 more source

Cutaneous lymphatics and skin diseases: mechanisms, imaging modalities, and future therapeutic strategies. [PDF]

Front Physiol
Chen N, Gu D, Yang W, Meng X, Liu T, Li D, Xu Y.   +6 more
europepmc   +1 more source

The Underestimated Role of Environmental Factors in the Prevention of Invasive Fungal Disease: Experience From a European Childhood Cancer Centre

Mycoses, Volume 69, Issue 7, July 2026.
ABSTRACT Background Immunocompromised children with hematologic malignancies or undergoing allogeneic haematopoietic stem cell transplantation (HSCT) are at high risk for invasive fungal diseases (IFDs). Reported incidence varies considerably due to heterogeneous diagnostic criteria, antifungal strategies and environmental conditions.
Stefano Malvestiti, Felicia Andresen, Markus Hufnagel, Carsten Speckmann, Brigitte Strahm, Tobias Feuchtinger, Alexander Puzik   +6 more
wiley   +1 more source

Gastrointestinal-Predominant ALK-Negative Systemic Anaplastic Large Cell Lymphoma Presenting as Fever of Unknown Origin: Case Report. [PDF]

Korean J Helicobacter Up Gastrointest Res
Kim CH, Lee SH.
europepmc   +1 more source

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025

Pigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.
ABSTRACT The 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting took place in Amsterdam, The Netherlands on October 25th, 2025. Several promising drug candidates are in development; however, there is still an urgent need for better prevention, detection, and treatment of uveal melanoma.
Andrew E. Aplin, Katherina Alsina, Allison S. Betof, Joseph Birkett, Marcus O. Butler, George Cole Jr., Rizwan Haq, Florian A. Karreth, Vinit B. Mahajan, Rahul Marpadga, Prithvi Mruthyunjaya, Paul Nathan, Jonas A. Nilsson, Gary Palmer, Joseph J. Sacco, Takami Sato, Sarah Stanhope, Pang‐ning Teng, Kyleigh LiPira   +18 more
wiley   +1 more source